The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

NEJM Evidence publishes positive results from pivotal bladder cancer clinical trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Positive results from the phase II/III QUILT 3.032 trial studying N-803 (nogapendekin alfa inbakicept), a novel IL-15 superagonist complex, plus BCG in adults with non-muscle invasive bladder cancer carcinoma in situ with or without Ta/T1 papillary disease were published in NEJM Evidence.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Urine test may improve bladder cancer diagnosis and guide treatment decision, Stanford-led study finds

A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose people with bladder cancer more accurately than current standard methods. The test also allows physicians to not only assess the cancer’s response to treatment but to predict whether immunotherapy or chemotherapy is likely to be most effective for each patient.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account